BeiGene, Ltd. BGNE NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score

73/100

5/7 Pass

SharesGrow Intrinsic Value

Income Statement Balance Sheet Cash Flow Statement

Annual Quarterly

BeiGene, Ltd. (BGNE) generated $1.13B in operating cash flow for fiscal year 2025. After capital expenditures of $185.84M, free cash flow was $941.74M.

Free cash flow margin was 17.6% of revenue. Cash conversion ratio was 3.93x, indicating earnings are backed by cash.

Criteria supported by this page:

HEALTH (83/100, Pass) — demonstrate the company can comfortably service its debt
MOAT (80/100, Pass) — $941.74M (17.6% FCF margin) supports a durable competitive advantage
INCOME (45/100) — Cash conversion ratio was 3.93x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 73/100 with 5/7 criteria passed.

SharesGrow 7-Criteria Score

73/100

SG Score

View full scorecard →

✓

VALUE

94/100

Price-to-Earnings & upside

→ Valuation

✓

FUTURE

85/100

Analyst consensus

→ Forecast

✗

PAST

25/100

→ Income

✓

HEALTH

83/100

Debt-to-Equity & liquidity

Proven by this page

✓

MOAT

80/100

Proven by this page

✓

GROWTH

100/100

→ Income

INCOME

45/100

→ Income

BeiGene, Ltd. Cash Flow History

Metric	TTM	FY2025	FY2024	FY2023	FY2022
Operating Cash Flow	$1.13B	$1.13B	$-140.63M	$-1.16B	$-1.5B
Capital Expenditure	$-490.8M	$-185.84M	$-529.14M	$-596.26M	$-469.1M
Free Cash Flow	$636.78M	$941.74M	$-669.77M	$-1.75B	$-1.97B